Susquehanna International Group, LLP Vaxcyte, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $11.7 Million - $19.5 Million	166,400 Added 571.82%	195,500 $22.3 Million
Q2 2024 Aug 15, 2024	SELL	$60.06 - $78.77 $942,942 - $1.24 Million	-15,700 Reduced 35.04%	29,100 $2.2 Million
Q1 2024 May 07, 2024	BUY	$59.79 - $81.05 $17,937 - $24,315	300 Added 0.67%	44,800 $3.06 Million
Q4 2023 Feb 14, 2024	BUY	$45.35 - $63.41 $1.61 Million - $2.26 Million	35,600 Added 400.0%	44,500 $2.79 Million
Q3 2023 Nov 14, 2023	SELL	$46.0 - $53.1 $984,400 - $1.14 Million	-21,400 Reduced 70.63%	8,900 $453,000
Q2 2023 Aug 11, 2023	BUY	$34.66 - $54.07 $221,823 - $346,048	6,400 Added 26.78%	30,300 $1.51 Million
Q1 2023 May 16, 2023	SELL	$36.27 - $47.2 $3.78 Million - $4.91 Million	-104,100 Reduced 81.33%	23,900 $895,000
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $2.15 Million - $5.01 Million	104,400 Added 442.37%	128,000 $6.14 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $511,884 - $673,308	23,600 New	23,600 $566,000

352

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.25B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.